H.C. Wainwright raised the firm’s price target on Vera Therapeutics to $25 from $10 and keeps a Buy rating on the shares. The analyst cites the positive ORIGIN data of atacicept in IgA nephropathy and a more positive view of the company’s competitive position for the target raise.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VERA:
- Chevron upgraded, SolarEdge downgraded: Wall Street’s top analyst calls
- Vera Therapeutics initiated with Buy, $27 target at Guggenheim
- Vera Therapeutics initiated with a Buy at Guggenheim
- Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results
- Vera Therapeutics announces upcoming milestones